Magnetic resonance-guided stereotactic body radiation therapy for pancreatic oligometastases from renal cell carcinoma
Stereotactic body radiation therapy (SBRT) may be a non-invasive strategy to treat patients with pancreatic oligometastases from renal cell carcinoma (RCC). We analyzed 11 patients treated with MR-guided SBRT to 31 pancreatic oligometastases. At a median follow-up of 31.6 months, 1-year and 2-year freedom from local progression was 100 % and 95 % (95 % CI 86-100 %), respectively. Moreover, 1-year and 2-year freedom from systemic therapy was 91 % (95 %CI 75-100 %) and 82 % (95 % CI 62-100 %), respectively. MR-guided SBRT may be a safe and effective treatment option for pancreatic oligometastases from RCC.
Authors
- Sasja F. Mulder (ORCID: https://orcid.org/0000-0002-8068-4240)
- Martijn Intven (ORCID: https://orcid.org/0000-0002-5068-5517)
- Gert J. Meijer (ORCID: https://orcid.org/0000-0001-7275-319X)
- Hidde Eijkelenkamp (ORCID: https://orcid.org/0000-0002-3645-2530)
- Guus Grimbergen (ORCID: https://orcid.org/0000-0002-3648-4786)
- Jonna K. van Vulpen
- Frank J. Wessels
Institutions
- Radboud University Nijmegen (NL)
- Radboud University Medical Center (NL)
- University Medical Center Utrecht (NL)
Publication Details
- Journal
- Physics and Imaging in Radiation Oncology
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1016/j.phro.2024.100683
- Citations
- 3
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.26